NRx Pharmaceuticals (NRXP)
(Delayed Data from NSDQ)
$3.25 USD
+0.30 (10.17%)
Updated Sep 29, 2025 04:00 PM ET
After-Market: $3.26 +0.01 (0.31%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth C Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
NRXP 3.25 +0.30(10.17%)
Will NRXP be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for NRXP based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for NRXP
Here's Why NRx Pharmaceuticals (NRXP) Is a Great 'Buy the Bottom' Stock Now
NRx Pharmaceuticals to Post Q4 Earnings: How to Play the Stock?
NRXP: What are Zacks experts saying now?
Zacks Private Portfolio Services
Best Momentum Stocks to Buy for January 6th
New Strong Buy Stocks for January 6th
Best Momentum Stocks to Buy for December 30th
Other News for NRXP
NRXP's Rating Maintained at 'Buy' by D. Boral Capital | NRXP Stock News
NRx Pharmaceuticals re-files abbreviated NDA for KETAFR
NRx Pharmaceuticals re-files abbreviated NDA for KETAFR
NRXP forms 20 Day Moving Average Support on September 26
NRX Pharmaceuticals Gains FDA Approval for KETAFREEā¢